A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells
about
Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasisProfile of palbociclib in the treatment of metastatic breast cancerTargeting the Checkpoint to Kill Cancer CellsTargeting CDK6 in cancer: State of the art and new insightsThe other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisRetinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsTargeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancersFOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathwaysTargeting CDK4 and CDK6: From Discovery to TherapyProteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexesA kinase-independent function of CDK6 links the cell cycle to tumor angiogenesisPD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem gliomaDual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.Recent advances of highly selective CDK4/6 inhibitors in breast cancerEmerging therapies for breast cancerModulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis.Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progressionCDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineCDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.The history and future of targeting cyclin-dependent kinases in cancer therapy.Cyclin-dependent kinase 6 phosphorylates NF-κB P65 at serine 536 and contributes to the regulation of inflammatory gene expression.Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis.Cellular senescence and aging: the role of B-MYBGlioblastoma multiforme formation and EMT: role of FoxM1 transcription factorCyclin D1 represses gluconeogenesis via inhibition of the transcriptional coactivator PGC1αMitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functionsOverexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.Recent progress in targeting cancer.MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.Forkhead Box M1 Is Essential for Nuclear Localization of Glioma-associated Oncogene Homolog 1 in Glioblastoma Multiforme Cells by Promoting Importin-7 Expression.Mechanistic insights into aging, cell-cycle progression, and stress response.Control of regional decidualization in implantation: Role of FoxM1 downstream of Hoxa10 and cyclin D3Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome Activity.CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
P2860
Q24613046-A11E229B-CFC3-48D4-A84B-B71E1AD95C6CQ26747737-3BBF4DC1-6BF6-4C7C-AC44-64E6801DCE05Q26795781-10F9ADC9-E48C-4693-8FE6-B9A4D64521A3Q26796499-E4F7A165-A1BA-42FE-90C4-A1FE269D8A47Q26865888-917B9A73-9DCA-40D2-B232-0045FC5C9DE7Q27022834-F6FE1123-F82E-4C22-BB95-8D29BB4A2814Q28069910-033648B1-832B-4669-89D9-6F739A28D9F9Q28076296-6C38C192-351A-4259-A88C-C9B2B230E7EEQ28082912-3D02A903-3161-4181-B24E-1C9EA23A8965Q28115646-B42321C1-8DB1-4DEA-ABF5-70CFFC4AD225Q28296641-E6A4CD5F-1A99-4519-A780-BBD56D9BE158Q28533981-3006C7B1-168C-4BD9-A58E-321870E64970Q30426051-AADDC803-95F8-4416-B8BA-0D08170C5EC5Q33560698-5E0DB6F4-7BD7-4841-9BEE-2EAE05EC534EQ33602076-B7C75912-6D9B-41B5-8240-0CB34FC32E7FQ33617949-8C3356F0-398D-4EB8-832E-8172572BDF46Q33645120-8D2FADB1-D210-45DB-881F-53B3A7FCC32FQ33762091-73FA00AF-C03F-4EA1-9CDA-F1BFA3713E91Q33827309-2F9F0777-06D5-4F6C-89B3-6F31F2959B84Q33851230-0FB0A200-C586-4401-A880-60A42E1354B2Q34004428-6ECFDF74-E060-4C3C-A46A-EC2CD1D69B1EQ34089034-30497E2E-1265-4063-A72E-6CDBD4105577Q34147910-4637CCCB-51EB-4211-BD0F-E55A2F901FB8Q34217662-0650F97C-6854-48F6-A9C3-D42773A8851CQ34227791-4760573D-469E-4E41-9088-6CFDA994E04FQ34460347-388392B6-44E4-4F19-B211-5E7171933122Q34540259-A7A65911-524F-4A8C-884E-21AFA53E8010Q35073171-5B78F0BF-3D84-40E7-A346-D4E097E82C32Q35093078-C37DCE18-04A9-47C7-8BF1-B802106EBC27Q35234273-B5CA9900-B459-4107-8039-1DE51FA82194Q35360473-46D6FE2B-B4E1-459B-81C6-A829668F1783Q35549264-3F82654B-6103-4254-BF80-AD1954FABED1Q35602152-021AEE02-2E6B-4F97-B383-C5E87E25147EQ35740782-5278E110-4819-401D-92DD-02366192EC1CQ35781547-59A9C399-D249-4F03-BA93-FAE4F79F9873Q35883866-554391B6-339B-44D7-B57D-DA03E3BE73FEQ36005664-973E353F-3239-45C7-9ADC-6CF7FF241095Q36039734-AC040205-A8AF-4BC0-8E4E-4EF7D9A036ABQ36092368-1B61104B-59EA-410D-9DFD-21C25EEE36D7Q36093810-743FA5B9-3B62-4B9C-9A57-5C25BA69F823
P2860
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@ast
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@en
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@en-gb
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@nl
type
label
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@ast
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@en
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@en-gb
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@nl
prefLabel
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@ast
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@en
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@en-gb
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@nl
P2093
P2860
P3181
P1433
P1476
A systematic screen for CDK4/6 ...... ce suppression in cancer cells
@en
P2093
Huili Zhai
Joel M Chick
Lars Anders
Marc Vidal
Per Hydbring
Piotr Sicinski
Stephen P Gygi
Yoon J Choi
P2860
P304
P3181
P356
10.1016/J.CCR.2011.10.001
P407
P577
2011-11-15T00:00:00Z